Browse > Home / FDA News / Pfizer to Pay $2.3 Billion, Undergo Annual Reviews for Off-Label Promotion

Pfizer to Pay $2.3 Billion, Undergo Annual Reviews for Off-Label Promotion

September 3, 2009

Pfizer to Pay $2.3 Billion, Undergo Annual Reviews with a view to Off-Label Promotion
Pfizer has agreed to a $2.3 billion arrangement — the largest healthcare deception establishment in Justice Department history — to resolve criminal and civil cases arising from the illegal promotion of several of its drugs. As a proceed of the investigation, the drugmaker is entering into a five-year corporate entireness agreement with the HHS Office of Inspector General that requires annual reviews of the company’s compliance program. Pharmacia & Upjohn, a Pfizer subsidiary, testament plead guilty to a felony violation of the Food, Drug and Cosmetic Act as being misbranding the anti-inflammatory drug Bextra (valdecoxib) through the intent to defraud or mislead and will pay $105 million in fines, Justice related in a press briefing Wednesday.

Written by Samanta · Filed Under FDA News